Skip to main content

August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology

Value-Based Healthcare Delivery: The Agenda for Oncology
Chase Doyle
Read More
FDA Approvals
Nivolumab Beats Docetaxel as Second-Line Therapy for Patients with NSCLC
Phoebe Starr
Read More
Searching for the Tipping Point in Drug Pricing
Caroline Helwick
Read More
FDA Approvals
Oncology Pipeline Full, and Not Just with Immunotherapies
Caroline Helwick, Wayne Kuznar
Read More
FDA Approvals
FDA Update
Read More
Aetna Examines Impact of Site of Service on Chemotherapy Cost
Caroline Helwick
Read More
Treating with Checkpoint Inhibitors—Figure $1 Million per Patient
Audrey Andrews
Read More
Researchers Dissect the Cost of Targeted Agents
Caroline Helwick
Read More
Bevacizumab Wins Cost-Effectiveness Contest in First-Line Metastatic Colorectal Cancer
Caroline Helwick
Read More
Will Necitumumab Be Cost-Effective?
Caroline Helwick
Read More
Page 1 of 4
Results 1 - 10 of 37